Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma Feb 7, 2017
Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms Jan 24, 2017
Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer Jan 18, 2017
Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of Analytical Development to Support BLA and IND Enabling Analytical Studies for Current and Future Clinical Programs Dec 19, 2016
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A Dec 13, 2016
Actinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AML Dec 12, 2016
Actinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual Meeting Dec 5, 2016
